You are here

Article info

Article menu

Download PDFPDF

XML
Case Report
Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

Authors

  • Mohammed Alnaggar Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China Department of Oncology, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Yan Xu Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Jingxia Li Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Junyi He Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Jibing Chen Department of Oncology, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China Department of Biological Treatment Center, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Man Li Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Qingling Wu Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Li Lin Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Yingqing Liang Department of Biological Treatment Center, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Xiaohua Wang Department of Biological Treatment Center, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Jiawei Li Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Yi Hu Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Yan Chen Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Kecheng Xu Department of Oncology, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China Department of Biological Treatment Center, Fuda Cancer Hospital, School of MedicineJinan University 510665 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Yangzhe Wu Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  • Zhinan Yin Biomedical Translational Research Institute and The First Affiliated HospitalJinan University 601 W Ave Huangpu 510632 Guangzhou Guangdong People’s Republic of China PubMed articlesGoogle scholar articles
  1. ↵n xukc{at}vip.163.com
  2. ↵o tyzwu{at}jnu.edu.cn
  3. ↵p zhinan.yin{at}yale.edu
View Full Text

Citation

Alnaggar M, Xu Y, Li J, et al
Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
Journal for ImmunoTherapy of Cancer 2019;7:36. doi: 10.1186/s40425-019-0501-8

Publication history

  • Received October 3, 2018
  • Accepted January 9, 2019
  • First published February 8, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.